



DIASORIN S.P.A.: DIASORIN RECEIVES FDA CLEARANCE TO MARKET FIVE LIAISON® PRODUCTS IN THE UNITED STATES

Saluggia, January 8th, 2009 – During the past two months, DiaSorin S.p.A., a company that operates in the global market for in vitro diagnostics, received FDA clearance to market five LIAISON products which aid in diagnosing such infectious diseases as Hepatitis A, Rubella, and the Type I and Type II Herpes Simplex Virus. These latest clearances brought the number of LIAISON-technology assays to 19, all of them specialty tests, that DiaSorin can offer in the United States. The diagnostic market accessible with these products is estimated at about US\$400 million. Until now, no diagnostic company was able to offer in the United States such a broad panel of infectious disease tests based on fully automated chemiluminescence immunoassay (CLIA) technology systems (LIAISON).

DiaSorin is recognized throughout the world as the leader in infectious disease diagnostics and the global revenues generated in this clinical area account for half of the Company' s total sales. The clearance of five tests for infectious diseases by the FDA during the last two months of 2008 represents a validation of the Company' s competencies and provides DiaSorin with an essential tool to achieve recognition as the market leader in the United States in infectious disease diagnostics, which represent 40% of the global market for in vitro diagnostics. Today, the company is already present in the United States with production and research facilities with a staff of more than 250 employees, which generated 25% of total group revenues.

“ The ability to offer in the U.S. market the broadest panel of tests to diagnose infectious diseases,” said Carlo Rosa, Chief Executive Officer of DiaSorin S.p.A., “ is a signal

achievement in the process of supporting the Company' s future growth, as it comes on the heels of the success attained this past year in the vitamin D market. We are confident that we will also earn in the U.S. market the high standing that we already enjoy in the rest of the world in the field of infectious diseases.”

About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. DiaSorin S.p.A. comprises 14 companies based in Europe, the United States, Central and South America and Asia. It has more than 1,000 employees, including 90 research and development specialists, and operates four manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany) and Stillwater (USA) and Dublin (Ireland). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.diasorin.com

Contacts:

Investor Relations Officer

Laura Villa

DiaSorin S.p.A.

laura.villa@diasorin.it

+39 0161487532

+39 348 15 11 542

Press Office

Carolina Mailander

c.mailander@mailander.it

+39 335 655 56 51

Bruno Caprioli

caprioli@mailander.it

+39 335 590 14 02

